Xeris Biopharma (XERS) director awarded new RSU and stock option grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Xeris Biopharma Holdings, Inc. director Garheng Kong reported receiving new equity awards as part of his compensation. He was granted 24,193 shares of common stock in the form of restricted stock units under the company’s 2018 Stock Option and Incentive Plan. Following this award, his direct common stock holdings total 238,337 shares.
He also received a stock option for 32,996 shares of common stock with an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock units and the stock options vest in full on the earlier of June 4, 2026 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through the vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Kong Garheng
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K |
| Grant/Award | Common Stock | 24,193 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,996 shares (Direct, null);
Common Stock — 238,337 shares (Direct, null)
Footnotes (1)
- These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Key Figures
RSU grant: 24,193 shares
Common shares held: 238,337 shares
Stock options granted: 32,996 options
+3 more
6 metrics
RSU grant
24,193 shares
Restricted stock unit grant to director Garheng Kong
Common shares held
238,337 shares
Direct common stock holdings after RSU grant
Stock options granted
32,996 options
New stock option award linked to common stock
Option exercise price
$6.15 per share
Exercise price for 32,996 stock options
Option expiration
June 4, 2036
Expiration date for stock option grant
Vesting date trigger
June 4, 2026
Awards vest on earlier of this date or next annual meeting
Key Terms
restricted stock unit, 2018 Stock Option and Incentive Plan, stock options, exercise price, +1 more
5 terms
restricted stock unit financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
2018 Stock Option and Incentive Plan financial
"acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
stock options financial
"These stock options were acquired pursuant to a grant under the Plan."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"transaction_price_per_share": "6.1500" and conversion_or_exercise_price": "6.1500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting"
FAQ
What insider transaction did Xeris Biopharma (XERS) report for Garheng Kong?
Xeris Biopharma reported that director Garheng Kong received equity awards as compensation. He was granted restricted stock units and stock options that increase his direct ownership and potential future stake in the company, subject to vesting conditions.
What stock options did Garheng Kong receive from Xeris Biopharma (XERS)?
He was granted stock options covering 32,996 shares of Xeris Biopharma common stock at an exercise price of $6.15 per share. These options give him the right to buy shares at that price if they vest and he chooses to exercise them before expiration.
When do Garheng Kong’s new Xeris Biopharma (XERS) equity awards vest?
Both the restricted stock units and the stock options vest in full on the earlier of June 4, 2026, or the date of Xeris Biopharma’s next annual meeting of stockholders. Vesting requires his continued service through the applicable date.
Under which plan were Garheng Kong’s Xeris Biopharma (XERS) awards granted?
The restricted stock units and stock options were granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan. This plan is used to provide equity-based compensation to directors and other participants to support long-term alignment with shareholders.